TW200700415A - New salt and polymorphs of the dpp-iv inhibitor - Google Patents

New salt and polymorphs of the dpp-iv inhibitor

Info

Publication number
TW200700415A
TW200700415A TW095109702A TW95109702A TW200700415A TW 200700415 A TW200700415 A TW 200700415A TW 095109702 A TW095109702 A TW 095109702A TW 95109702 A TW95109702 A TW 95109702A TW 200700415 A TW200700415 A TW 200700415A
Authority
TW
Taiwan
Prior art keywords
dpp
polymorphs
inhibitor
new salt
compound
Prior art date
Application number
TW095109702A
Other languages
English (en)
Inventor
Stefan Abrecht
Andre Gerard Bubendorf
Stephan Goetzoe
Olaf Grassmann
Francois Montavon
Regina Moog
Franziska Rohrer
Armin Ruf
Michelangelo Scalone
Urs Schwitter
Shaoning Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200700415A publication Critical patent/TW200700415A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095109702A 2005-03-22 2006-03-21 New salt and polymorphs of the dpp-iv inhibitor TW200700415A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102251 2005-03-22

Publications (1)

Publication Number Publication Date
TW200700415A true TW200700415A (en) 2007-01-01

Family

ID=36406081

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095109702A TW200700415A (en) 2005-03-22 2006-03-21 New salt and polymorphs of the dpp-iv inhibitor

Country Status (17)

Country Link
US (1) US7772264B2 (zh)
EP (1) EP1888571A2 (zh)
JP (1) JP5043825B2 (zh)
KR (1) KR20070113305A (zh)
CN (1) CN101146801A (zh)
AR (1) AR055570A1 (zh)
AU (1) AU2006226447B2 (zh)
BR (1) BRPI0609580A2 (zh)
CA (1) CA2600203C (zh)
DO (1) DOP2006000066A (zh)
GT (1) GT200600125A (zh)
IL (1) IL185768A0 (zh)
MX (1) MX2007011546A (zh)
PA (1) PA8666701A1 (zh)
PE (1) PE20061109A1 (zh)
TW (1) TW200700415A (zh)
WO (1) WO2006100181A2 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN103816158A (zh) 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
CZ2008512A3 (cs) 2008-08-26 2010-03-10 Zentiva, A. S Zpusob prípravy vysoce cistého vildagliptinu
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
BRPI1013639A2 (pt) 2009-02-13 2016-04-19 Boehringer Ingelheim Int medicamentos antidiabéticos
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103787944A (zh) * 2012-11-01 2014-05-14 天津药物研究院 1-(2-氯乙酰基)-2-(s)-腈基吡咯烷的制备方法
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN104262227B (zh) * 2014-09-16 2018-09-18 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN106699627A (zh) * 2016-12-29 2017-05-24 青岛黄海制药有限责任公司 一种多相复式非连续生产法制备1‑(2‑氯乙酰基)‑2‑(s)‑氰基吡咯烷的方法
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07247246A (ja) * 1994-03-09 1995-09-26 Daicel Chem Ind Ltd １−フェニル−３−ブチン誘導体とその製造方法
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
DE19755436A1 (de) 1997-12-13 1999-06-24 Beiersdorf Ag Verfahren zur zumindest partiellen direkten Beschichtung eines dehnfähigen Trägermaterials mit einer Haftklebemasse
NZ501896A (en) * 1998-03-30 2000-11-24 Japan Tobacco Inc Process for producing isoxazolidinedione compound
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
NZ538956A (en) * 2002-08-29 2006-08-31 Taisho Pharmaceutical Co Ltd Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivative used to inhibit dipeptidyl peptidase IV (DPPIV)
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process

Also Published As

Publication number Publication date
DOP2006000066A (es) 2006-09-30
WO2006100181A2 (en) 2006-09-28
JP2008534470A (ja) 2008-08-28
US20060217428A1 (en) 2006-09-28
CN101146801A (zh) 2008-03-19
BRPI0609580A2 (pt) 2010-04-20
AR055570A1 (es) 2007-08-22
PE20061109A1 (es) 2006-10-13
AU2006226447A1 (en) 2006-09-28
MX2007011546A (es) 2007-10-19
EP1888571A2 (en) 2008-02-20
US7772264B2 (en) 2010-08-10
AU2006226447B2 (en) 2009-07-16
CA2600203C (en) 2012-12-04
CA2600203A1 (en) 2006-09-28
JP5043825B2 (ja) 2012-10-10
GT200600125A (es) 2007-03-16
WO2006100181A3 (en) 2006-11-30
PA8666701A1 (es) 2006-12-07
IL185768A0 (en) 2008-01-06
KR20070113305A (ko) 2007-11-28

Similar Documents

Publication Publication Date Title
TW200700415A (en) New salt and polymorphs of the dpp-iv inhibitor
ATE482947T1 (de) Neues salz und polymorph des dpp-iv-hemmers
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
MX2007011848A (es) Antagonistas del receptor de procineticina i.
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
WO2007041077A3 (en) Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
EP2190428A4 (en) HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
TN2011000201A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase - iv inhibitors for the treatment or prevention of diabetes
ZA200710609B (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
ZA200704154B (en) Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes
EP1896459A4 (en) NOVEL 2-AZETIDINONE DERIVATIVES AS INHIBITORS OF CHOLESTEROL ABSORPTION FOR THE TREATMENT OF HYPERLIPIDEMIA CONDITIONS
IL191629A0 (en) Tricyclic amide derivatives useful for treating obesity
EP1758854A4 (en) PYRROLIDIN-3-YLE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
TW200728258A (en) Novel compounds
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2007041112A3 (en) Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas